How Azevan's programs may matter to you.
We are committed to advancing first-in-class V1a receptor antagonist therapies for serious conditions where no approved drugs are available and current treatments are off-label and limited by significant side effect risks. Below is a plain-language summary of our programs and how to engage with them today.
Plain-language overview of our programs.
Fragile X Syndrome — anxiety and aggression
Fragile X syndrome is a genetically defined neurodevelopmental disorder. Anxiety and aggression are prominent features that interfere with social interactions and daily activities. Currently used therapeutics are off-label and often limited by safety and tolerability concerns. A new Phase 2 study of SRX246, funded by the Congressionally Directed Medical Research Program, is starting in Q3 2026 and is designed to allow more patients to participate by incorporating home visits and eliminating the need to go to a clinic.
Mild Traumatic Brain Injury (mTBI)
About 90% of TBI cases are mild — typically concussions — and many patients experience post-concussion symptoms that impact mental health and memory function. There are no approved drugs that improve neurological outcomes. Our injury-modifying program, with SRX251 and AVN849, has shown reductions in injury severity and preservation of cognitive function in translational animal models.
Huntington's Disease — neuropsychiatric symptoms
Anger and aggression are common in Huntington's disease and are a leading cause of institutionalization. They affect not only patients but also families and caregivers. There are no approved treatments for these symptoms. Our investigational drug, SRX246, has shown clinically meaningful benefit in a Phase 2 trial without serious adverse events.
Intermittent Explosive Disorder
Intermittent Explosive Disorder (IED) involves recurrent episodes of severe aggression that cause distress and impairment. A Phase 2 trial of SRX246 in IED showed reductions in severe aggression episodes and disability days, with excellent safety and tolerability.
How to participate.
The most direct way to access an investigational treatment such as SRX246 is by enrolling in one of our clinical trials. Information about active studies appears in our news section and on ClinicalTrials.gov. If you are a patient, family member, caregiver, or clinician interested in a trial, please consult your physician.
See trial updates → Search ClinicalTrials.gov →Expanded access.
At Azevan, we are committed to developing our first-in-class V1a receptor antagonist, SRX246, for the treatment of mood and behavior disorders in patients with neurodegenerative diseases such as Huntington's disease. The FDA has granted Fast Track Designation of SRX246 for this use. Our current focus is to complete our ongoing and planned clinical trials to demonstrate safety and efficacy in order to obtain regulatory approval and provide widespread availability of SRX246.
Prior to regulatory approval by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities, patients gain access to investigational treatments such as SRX246 by participating in clinical trials. Expanded access — also called compassionate use — enables some patients with serious or life-threatening diseases who would not have otherwise met the enrollment criteria for the clinical trials in progress to gain access to investigational treatments. Unlike use of an investigational new drug in a clinical trial setting, the primary purpose of expanded access is to use the drug for patient treatment, rather than to gather data on safety, tolerability, and effectiveness.
Accordingly, while clinical trials are ongoing, we believe participation in our clinical trials is the only safe and appropriate way to access SRX246.